Back to Journals » ClinicoEconomics and Outcomes Research » Volume 11
![](https://www.dovepress.com/cr_data/cache/journal_image/29/cope/thumb_100_1000_100.jpg)
ClinicoEconomics and Outcomes Research
ISSN: 1178-6981
- View all (876)
- Volume 16, 2024 (29)
- Volume 15, 2023 (67)
- Volume 14, 2022 (61)
- Volume 13, 2021 (90)
- Volume 12, 2020 (70)
- Volume 11, 2019 (71)
- Volume 10, 2018 (77)
- Volume 9, 2017 (77)
- Volume 8, 2016 (73)
- Volume 7, 2015 (64)
- Volume 6, 2014 (53)
- Volume 5, 2013 (59)
- Volume 4, 2012 (41)
- Volume 3, 2011 (19)
- Volume 2, 2010 (16)
- Volume 1, 2009 (9)
Archive: Volume 11, 2019
- default (71)
- Health-related Outcomes and Economic Burden in Japan. Focus on: Inflammatory Bowel Disease, Multiple Sclerosis, and Depression (4)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
![Plain language summary](assets/img/article_icons/plain-language.png)
Healthcare Costs of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
Best JH, Kong AM, Smith DM, Abbass I, Michalska M
ClinicoEconomics and Outcomes Research 2019, 11:799-807
Published Date: 23 December 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
North American cost analysis of brand name versus generic drugs for the treatment of glaucoma
Malvankar-Mehta MS, Feng L, Hutnik CML
ClinicoEconomics and Outcomes Research 2019, 11:789-798
Published Date: 16 December 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Canadian Medication Cost Savings Associated with Combinatorial Pharmacogenomic Guidance for Psychiatric Medications
Tanner JA, Brown LC, Yu K, Li J, Dechairo BM
ClinicoEconomics and Outcomes Research 2019, 11:779-787
Published Date: 9 December 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-Effectiveness Analysis of the Adjunctive Therapy of Ivabradine for the Treatment of Heart Failure with Reduced Ejection Fraction
Krittayaphong R, Yadee J, Permsuwan U
ClinicoEconomics and Outcomes Research 2019, 11:767-777
Published Date: 5 December 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain
Cevey M, Calvo-Alén J, Crespo C, Robles-Marhuenda A, Smolen L, Cortés-Hernández J
ClinicoEconomics and Outcomes Research 2019, 11:757-765
Published Date: 5 December 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Real-World Economic Outcomes of Brexpiprazole and Extended-Release Quetiapine Adjunctive Use in Major Depressive Disorder
Seetasith A, Greene M, Hartry A, Burudpakdee C
ClinicoEconomics and Outcomes Research 2019, 11:741-755
Published Date: 4 December 2019
![Video](assets/img/article_icons/video.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-Effectiveness Of Culture-Based Versus Empirical Antibiotic Treatment For Hospitalized Adults With Community-Acquired Pneumonia In Indonesia: A Real-World Patient-Database Study
![](assets/img/youtube_social_icon_dark.png)
![](http://img.youtube.com/vi/zGnPtAIZYWA/1.jpg)
Purba AKR, Ascobat P, Muchtar A, Wulandari L, Dik JW, d'Arqom A, Postma MJ
ClinicoEconomics and Outcomes Research 2019, 11:729-739
Published Date: 29 November 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
![Plain language summary](assets/img/article_icons/plain-language.png)
Comparison Of Methods To Estimate Disease-Related Cost And Healthcare Resource Utilization For Autoimmune Diseases In Administrative Claims Databases
Schroeder KM, Gelwicks S, Naegeli AN, Heaton PC
ClinicoEconomics and Outcomes Research 2019, 11:713-727
Published Date: 26 November 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The Burden, Future Trends, And Economic Impact Of Lung Cancer In Saudi Arabia
Da'ar OB, Zaatreh YA, Saad AA, Alkaiyat M, Pasha T, Ahmed AE, Bustami R, Alkattan K, Jazieh AR
ClinicoEconomics and Outcomes Research 2019, 11:703-712
Published Date: 19 November 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Comparative Cost Analysis Of Intravenous And Subcutaneous Administration Of Rituximab In Lymphoma Patients
Delgado Sánchez O, Gutiérrez A, do Pazo F, Ginés J, Martorell C, Boyeras B, Bento L, Garcia-Recio M, Sampol A
ClinicoEconomics and Outcomes Research 2019, 11:695-701
Published Date: 18 November 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain
Arenaza A, Diez R, Esteve J, Di Nicolantonio R, Gostkorzewicz J, Martínez C, Martínez Llinàs D, Martinez-Lopez J, Montesinos P, Moure-Fernández A, Sierra J, Vinent JL
ClinicoEconomics and Outcomes Research 2019, 11:683-694
Published Date: 13 November 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States
Tremblay G, Said Q, Roy AN, Cai B, Ashton Garib S, Hearnden J, Forsythe A
ClinicoEconomics and Outcomes Research 2019, 11:673-681
Published Date: 12 November 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives
Kongnakorn T, Bharmal M, Kearney M, Phatak H, Benedict A, Bhanegaonkar A, Galsky M
ClinicoEconomics and Outcomes Research 2019, 11:659-672
Published Date: 8 November 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Moving Toward Universal Health Coverage: Four Decades Of Experience From The Iranian Health System
Alinia C, Davoodi Lahijan J
ClinicoEconomics and Outcomes Research 2019, 11:651-657
Published Date: 7 November 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-Effectiveness Of The SQ® Grass SLIT-Tablet In Children With Allergic Rhinitis: A German Payer Perspective
Vogelberg C, Hamelmann E, Wahn U, Domdey A, Pollock RF, Grand TS
ClinicoEconomics and Outcomes Research 2019, 11:637-649
Published Date: 6 November 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A Cost-Effectiveness Analysis Of An Adenocarcinoma Risk Prediction Multi-Biomarker Assay For Patients With Barrett’s Esophagus
Hao J, Critchley-Thorne R, Diehl DL, Snyder SR
ClinicoEconomics and Outcomes Research 2019, 11:623-635
Published Date: 25 October 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Estimation Of The Quality Of Life Benefits Associated With Treatment For Spinal Muscular Atrophy
Lloyd AJ, Thompson R, Gallop K, Teynor M
ClinicoEconomics and Outcomes Research 2019, 11:615-622
Published Date: 25 October 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
![Plain language summary](assets/img/article_icons/plain-language.png)
Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy
Pöhlmann J, Montagnoli R, Lastoria G, Parekh W, Markert M, Hunt B
ClinicoEconomics and Outcomes Research 2019, 11:605-614
Published Date: 7 October 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement
Delgado MF, Abdelrahman AM, Terahi M, Miro Quesada Woll JJ, Gil-Carrasco F, Cook C, Benharbit M, Boisseau S, Chung E, Hadjiat Y, Gomes JAP
ClinicoEconomics and Outcomes Research 2019, 11:591-604
Published Date: 27 September 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Health economic evaluation of peritoneal dialysis based on cost-effectiveness in Japan: a preliminary study
Takura T, Hiramatsu M, Nakamoto H, Kuragano T, Minakuchi J, Ishida H, Nakayama M, Takahashi S, Kawanishi H
ClinicoEconomics and Outcomes Research 2019, 11:579-590
Published Date: 25 September 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Social Return On Investment For Patient Treated By Continuous Ambulatory Peritoneal Dialysis: A Case Study In Ubon Ratchathani Province, Thailand
Lophongpanit P, Tongsiri S, Thongprasert N
ClinicoEconomics and Outcomes Research 2019, 11:569-578
Published Date: 23 September 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting [Corrigendum]
Hodgson RE
ClinicoEconomics and Outcomes Research 2019, 11:567-568
Published Date: 9 September 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons
Tremblay G, Westley T, Cappelleri JC, Arondekar B, Chan G, Bell TJ, Briggs A
ClinicoEconomics and Outcomes Research 2019, 11:551-565
Published Date: 6 September 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Patient and economic burdens of postherpetic neuralgia in China
Yu SY, Fan BF, Yang F, DiBonaventura M, Chen YX, Li RY, King-Concialdi K, Kudel I, Hlavacek P, Hopps M, Udall M, Sadosky A, Cappelleri JC
ClinicoEconomics and Outcomes Research 2019, 11:539-550
Published Date: 3 September 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-consequence analysis for human recombinant growth hormone (r-hGH) treatment administered via different devices in children with growth hormone deficiency in Italy
Foo J, Maghnie M, Colao A, Vlachaki I, Colombo G
ClinicoEconomics and Outcomes Research 2019, 11:525-537
Published Date: 22 August 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting
Hodgson RE
ClinicoEconomics and Outcomes Research 2019, 11:517-524
Published Date: 13 August 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer [Corrigendum]
Bretoni A, Ferrario L, Foglia E
ClinicoEconomics and Outcomes Research 2019, 11:515-516
Published Date: 6 August 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Characteristics and outcome of high-cost ICU patients
Aung YN, Nur AM, Ismail A, Aljunid SM
ClinicoEconomics and Outcomes Research 2019, 11:505-513
Published Date: 2 August 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-effectiveness of adding Endocuff® to standard colonoscopies for interval colorectal cancer screening
Yu TM, Tradonsky A, Tang J, Arnold RJG
ClinicoEconomics and Outcomes Research 2019, 11:487-504
Published Date: 31 July 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A Canadian cost-effectiveness analysis of SAPIEN 3 transcatheter aortic valve implantation compared with surgery, in intermediate and high-risk severe aortic stenosis patients
Tarride JE, Luong T, Goodall G, Burke N, Blackhouse G
ClinicoEconomics and Outcomes Research 2019, 11:477-486
Published Date: 29 July 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain
Sánchez-Cenizo L, Aller J, Martínez-Sesmero JM, Mir N, Peral C, Rubio-Rodríguez D, Rubio-Terrés C
ClinicoEconomics and Outcomes Research 2019, 11:465-475
Published Date: 22 July 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-effectiveness and budget impact analysis of viscosupplementation with hylan G-F 20 for knee and hip osteoarthritis
Migliore A, Integlia D, Pompilio G, Di Giuseppe F, Aru C, Brown T
ClinicoEconomics and Outcomes Research 2019, 11:453-464
Published Date: 22 July 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Clinical and economic burden of head and neck cancer: a nationwide retrospective cohort study from France
Schernberg A, Sagaon-Teyssier L, Schwarzinger M
ClinicoEconomics and Outcomes Research 2019, 11:441-451
Published Date: 22 July 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
![Plain language summary](assets/img/article_icons/plain-language.png)
Untangling the clinical and economic burden of hospitalization for cardiac amyloidosis in the United States
Quock TP, Yan T, Tieu R, D'Souza A, Broder MS
ClinicoEconomics and Outcomes Research 2019, 11:431-439
Published Date: 15 July 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand
Deerochanawong C, Kosachunhanun N, Gadekar AV, Chotikanokrat P, Permsuwan U
ClinicoEconomics and Outcomes Research 2019, 11:423-430
Published Date: 11 July 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The added burden of depression in patients with osteoarthritis in Japan
Tsuji T, Nakata K, Vietri J, Jaffe DH
ClinicoEconomics and Outcomes Research 2019, 11:411-421
Published Date: 20 June 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Abatacept: from a budget impact model to cost-effectiveness analysis – data from RCT and real life
Benucci M, Damiani A, Manfredi M, Infantino M, Grossi V, Li Gobbi F
ClinicoEconomics and Outcomes Research 2019, 11:405-409
Published Date: 7 June 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-effectiveness analysis of baricitinib versus adalimumab for the treatment of moderate-to-severe rheumatoid arthritis in Spain
Schlueter M, Finn E, Díaz S, Dilla T, Inciarte-Mundo J, Fakhouri W
ClinicoEconomics and Outcomes Research 2019, 11:395-403
Published Date: 6 June 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Heart failure hospitalization reduction and cost savings achieved by improved delivery of effective biventricular pacing: economic implications of the OLE study under the US setting
Hernández-Madrid A, Lu X, Tsintzos SI, Fagan DH, Klepfer RN, Matía R, Chung ES
ClinicoEconomics and Outcomes Research 2019, 11:385-393
Published Date: 6 June 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Association of tumor location with economic outcomes and air leak complications in thoracic lobectomies: results from a national hospital billing dataset
Bhora F, Ghosh SK, Kassis E, Yoo A, Ramisetti S, Johnston SS, Rehmani S, Kalsekar I
ClinicoEconomics and Outcomes Research 2019, 11:373-383
Published Date: 6 June 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Treatment patterns and economic outcomes in patients with juvenile idiopathic arthritis
Marshall A, Gupta K, Pazirandeh M, Bonafede M, McMorrow D
ClinicoEconomics and Outcomes Research 2019, 11:361-371
Published Date: 31 May 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Budget impact model of avelumab in patients with metastatic merkel cell carcinoma in the US
Bharmal M, Kearney M, Zheng Y, Phatak H
ClinicoEconomics and Outcomes Research 2019, 11:349-359
Published Date: 22 May 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
An iron triangle ROI model for health care
van der Goes DN, Edwardson N, Rayamajhee V, Hollis C, Hunter D
ClinicoEconomics and Outcomes Research 2019, 11:335-348
Published Date: 10 May 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Electronic referral systems in health care: a scoping review
Azamar-Alonso A, Costa AP, Huebner LA, Tarride JE
ClinicoEconomics and Outcomes Research 2019, 11:325-333
Published Date: 6 May 2019
![Noteworthy comment: This study assessed different methods to determine whether high ICERs (incremental cost-effectiveness ratio) are caused by high drug costs, high ‘background costs’ or a combination of both and how different approaches can alter the impact of background costs on the ICER where the marginal cost-effectiveness ratio is close to, or above, the cost-effectiveness threshold.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The impact of increased post-progression survival on the cost-effectiveness of interventions in oncology
Retzler J, Davies H, Jenks M, Kiff C, Taylor M
ClinicoEconomics and Outcomes Research 2019, 11:309-324
Published Date: 3 May 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-effectiveness of fractional exhaled nitric oxide (FeNO) measurement in predicting response to omalizumab in asthma
Brooks EA, Massanari M, Hanania NA, Weiner DJ
ClinicoEconomics and Outcomes Research 2019, 11:301-307
Published Date: 17 April 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer
Bretoni A, Ferrario L, Foglia E
ClinicoEconomics and Outcomes Research 2019, 11:283-300
Published Date: 17 April 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
![Plain language summary](assets/img/article_icons/plain-language.png)
Cost of achieving HbA1c and weight loss treatment targets with IDegLira vs insulin glargine U100 plus insulin aspart in the USA
Billings LK, Mocarski M, Basse A, Hunt B, Valentine WJ, Jodar E
ClinicoEconomics and Outcomes Research 2019, 11:271-282
Published Date: 21 March 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-effectiveness model for a hypothetical monotherapy vs standard of care in adult patients with treatment-resistant depression
Wang ST, Anderson IM, Mitchell D, Johnson SJ, Shiozawa A
ClinicoEconomics and Outcomes Research 2019, 11:257-270
Published Date: 14 March 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-of-illness of knee osteoarthritis: potential cost savings by not undergoing arthroplasty within the first 2 years
Ong KL, Runa M, Lau E, Altman RD
ClinicoEconomics and Outcomes Research 2019, 11:245-255
Published Date: 14 March 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
![Thematic Series](assets/img/article_icons/thematic-series.png)
Health-related quality of life outcomes, economic burden, and associated costs among diagnosed and undiagnosed depression patients in Japan
Yamabe K, Liebert R, Flores N, Pashos CL
ClinicoEconomics and Outcomes Research 2019, 11:233-243
Published Date: 12 March 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
![Thematic Series](assets/img/article_icons/thematic-series.png)
Health-related quality of life outcomes and economic burden of inflammatory bowel disease in Japan
Yamabe K, Liebert R, Flores N, Pashos CL
ClinicoEconomics and Outcomes Research 2019, 11:221-232
Published Date: 12 March 2019
![Video](assets/img/article_icons/video.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
![Plain language summary](assets/img/article_icons/plain-language.png)
Relative value assessment: characterizing the benefit of oncology therapies through diverse survival metrics from a US perspective
![](assets/img/youtube_social_icon_dark.png)
![](http://img.youtube.com/vi/bFEOTH4JweM/1.jpg)
Macaulay R, Ahuja A, Ademisoye E, Juarez-Garcia A, Shaw JW
ClinicoEconomics and Outcomes Research 2019, 11:199-219
Published Date: 19 March 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Reduction of direct costs in high-risk lumbar discectomy patients during the 90-day post-operative period through annular closure
Thaci B, McGirt MJ, Ammerman JM, Thomé C, Kim KD, Ament JD
ClinicoEconomics and Outcomes Research 2019, 11:191-197
Published Date: 28 February 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
![Plain language summary](assets/img/article_icons/plain-language.png)
Health care utilization and costs following amplified versus non-amplified molecular probe testing for symptomatic patients with suspected vulvovaginitis: a US commercial payer population
Ackerman SJ, Knight T, Wahl PM, Cartwright CP
ClinicoEconomics and Outcomes Research 2019, 11:179-189
Published Date: 20 February 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A cost-consequence analysis of parecoxib and opioids vs opioids alone for postoperative pain: Chinese perspective
Barra M, Remák E, Liu DD, Xie L, Abraham L, Sadosky AB
ClinicoEconomics and Outcomes Research 2019, 11:169-177
Published Date: 22 February 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland
Purmonen T, Puolakka K, Mishra D, Gunda P, Martikainen J
ClinicoEconomics and Outcomes Research 2019, 11:159-168
Published Date: 15 February 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Catastrophic health expenditure of Vietnamese patients with gallstone diseases – a case for health insurance policy revaluation
Tran BX, Tran TD, Nathan N, Ngo CQ, Nguyen LT, Nguyen LH, Nguyen HLT, Nguyen CT, Do HP, Nguyen THT, Tran TT, Thai TPT, Dang AK, Nguyen NB, Latkin CA, Ho CSH, Ho RCM
ClinicoEconomics and Outcomes Research 2019, 11:151-158
Published Date: 11 February 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Ninety-day postoperative cost in primary total hip arthroplasty: an economic model comparing surgical approaches
Miller LE, Martinson MS, Gondusky JS, Kamath AF, Boettner F, Bhattacharyya SK
ClinicoEconomics and Outcomes Research 2019, 11:145-149
Published Date: 7 February 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective study
Demiralp B, Koenig L, Kala J, Feng C, Hamlett EG, Steele-Adjognon M, Ward S
ClinicoEconomics and Outcomes Research 2019, 11:129-144
Published Date: 7 February 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Sarilumab monotherapy compared with adalimumab monotherapy for the treatment of moderately to severely active rheumatoid arthritis: an analysis of incremental cost per effectively treated patient
Fournier M, Chen C, Kuznik A, Proudfoot C, Mallya UG, Michaud K
ClinicoEconomics and Outcomes Research 2019, 11:117-128
Published Date: 5 February 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Economic impact of pharmacist interventions on correction of stress-related mucosal damage prophylaxis practice
Mahmoudi L, Mohammadi R, Niknam R
ClinicoEconomics and Outcomes Research 2019, 11:111-116
Published Date: 25 January 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Comparative analysis of US real-world dosing patterns and direct infusion-related costs for matched cohorts of rheumatoid arthritis patients treated with infliximab or intravenous golimumab
Ellis LA, Malangone-Monaco E, Varker H, Stetsovsky D, Kubacki M, DeHoratius RJ, Kafka S
ClinicoEconomics and Outcomes Research 2019, 11:99-110
Published Date: 15 January 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Health-related quality of life in acute myeloid leukemia patients not eligible for intensive chemotherapy: results of a systematic literature review
Forsythe A, Kwon CS, Bell T, Smith TA, Arondekar B
ClinicoEconomics and Outcomes Research 2019, 11:87-98
Published Date: 14 January 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Budget impact analysis of sarilumab for the treatment of rheumatoid arthritis in patients with an inadequate response to conventional synthetic DMARD or TNF inhibitor therapies [Corrigendum]
Ferrufino CP, Munakata J, Wei W, Proudfoot C, Kuznik A, Boklage SH, Chen C
ClinicoEconomics and Outcomes Research 2019, 11:83-85
Published Date: 14 January 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Cost-effectiveness of sensor-augmented insulin pump therapy vs continuous subcutaneous insulin infusion in patients with type 1 diabetes in the Netherlands
Roze S, Smith-Palmer J, de Portu S, Dalbaere A, de Brouwer B, de Valk HW
ClinicoEconomics and Outcomes Research 2019, 11:73-82
Published Date: 14 January 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
![Thematic Series](assets/img/article_icons/thematic-series.png)
Health-related outcomes, health care resource utilization, and costs of multiple sclerosis in Japan compared with US and five EU countries
Yamabe K, DiBonaventura MD, Pashos CL
ClinicoEconomics and Outcomes Research 2019, 11:61-71
Published Date: 7 January 2019
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Impact of migraine on health care utilization and expenses in obese adults: a US population-based study
Wu J, Davis-Ajami ML, Lu ZK
ClinicoEconomics and Outcomes Research 2019, 11:51-59
Published Date: 31 December 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Systematic literature review of treatment patterns for venous thromboembolism patients during transitions from inpatient to post-discharge settings
Trocio J, Rosen VM, Gupta A, Dina O, Vo L, Hlavacek P, Rosenblatt L
ClinicoEconomics and Outcomes Research 2019, 11:23-49
Published Date: 19 December 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Indirect costs associated with premature mortality among those with veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan dysfunction post-hematopoietic stem-cell-transplant
Zhou ZY, Tang W, Villa KF
ClinicoEconomics and Outcomes Research 2019, 11:13-22
Published Date: 17 December 2018
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
A US hospital budget impact analysis of a skin closure system compared with standard of care in hip and knee arthroplasty
Sadik K, Flener J, Gargiulo J, Post Z, Wurzelbacher S, Hogan A, Hollmann S, Ferko N
ClinicoEconomics and Outcomes Research 2019, 11:1-11
Published Date: 17 December 2018